Cerus Q1 revenue rises, beats estimates

Cerus

30/04/2026 21:12

Overview

Blood safety technology firm's Q1 revenue rose 23% yr/yr, beating analyst expectations

Q1 adjusted EBITDA beat consensus, driven by strong INTERCEPT Fibrinogen Complex demand

Company raised full-year 2026 product revenue guidance to $227 mln-$231 mln, up 10%-12% yr/yr

Outlook

Cerus raises 2026 product revenue guidance to $227 mln-$231 mln, up 10%-12% from 2025

Company expects 2026 IFC revenue between $22 mln and $24 mln

Cerus cites anticipated regulatory and clinical milestones as catalysts for 2026

Result Drivers

IFC DEMAND - Co said Q1 growth was primarily driven by increased demand for INTERCEPT Fibrinogen Complex, with volumes up about 120% yr/yr and higher U.S. sales

PLATELET FRANCHISE - Global platelet franchise contributed to product revenue growth, per company

GOVERNMENT CONTRACTS - Higher government contract revenue driven by BARDA and Department of Defense projects

Company press release: ID:nBw3cdwY3a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$59.90 mln
$53.17 mln (3 Analysts)
Q1 EPS
-$0.01
Q1 Net Income
-$1.60 mln
Q1 Adjusted EBITDA
Beat
$4 mln
$33,330 (3 Analysts)
Q1 Gross Margin
52.00%
Q1 Gross Profit
$27.90 mln
Q1 Operating Expenses
$34.48 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Cerus Corp is $5.00, about 160.4% above its April 29 closing price of $1.92

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)